In the past decade, there have been substantial advancements in treating acute myeloid leukemia (AML). Despite this progress, there is a lack of up-to-date RWE on how these changes have influenced survival rates. Additionally, previous studies have shown varying outcomes among different demographics, but there is limited information on how newer treatments have affected survival in diverse groups in real-life situations.
This study aims to fill these gaps by analyzing the latest trends in overall survival among AML patients and exploring the links between race, ethnicity, socioeconomic status (SES), and survival rates over time.
Why this matters
This study underscores the continual challenges in AML treatment, revealing higher mortality risks among individuals in the lowest SES group which has persisted in recent years despite new therapies. Surprisingly, race and ethnicity had limited impact on survival. Stagnant first-line treatment rates and unchanged survival outcomes in community-based settings highlight the urgent need for accessible therapies and comprehensive policies to address SES disparities and improve outcomes for patients with AML.